Journal of Lipid Research
Volume 60, Issue 12, December 2019, Pages 1996-2005
Journal home page for Journal of Lipid Research

Research Articles
Epoxyeicosatrienoic acid (EET)-stimulated angiogenesis is mediated by epoxy hydroxyeicosatrienoic acids (EHETs) formed from COX-2

https://doi.org/10.1194/jlr.M094219Get rights and content
Under a Creative Commons license
open access

Epoxyeicosatrienoic acids (EETs) are formed from the metabolism of arachidonic acid by cytochrome P450s. EETs promote angiogenesis linked to tumor growth in various cancer models that is attenuated in vivo by cyclooxygenase 2 (COX-2) inhibitors. This study further defines a role for COX-2 in mediating endothelial EET metabolism promoting angiogenesis. Using human aortic endothelial cells (HAECs), we quantified 8,9-EET-induced tube formation and cell migration as indicators of angiogenic potential in the presence and absence of a COX-2 inducer [phorbol 12,13-dibutyrate (PDBu)]. The angiogenic response to 8,9-EET in the presence of PDBu was 3-fold that elicited by 8,9-EET stabilized with a soluble epoxide hydrolase inhibitor (t-TUCB). Contributing to this response was the COX-2 metabolite of 8,9-EET, the 11-hydroxy-8,9-EET (8,9,11-EHET), which exogenously enhanced angiogenic responses in HAECs at levels comparable to those elicited by vascular endothelial growth factor (VEGF). In contrast, the 15-hydroxy-8,9-EET isomer was also formed but inactive. The 8,9,11-EHET also promoted expression of the VEGF family of tyrosine kinase receptors. These results indicate that 8,9-EET-stimulated angiogenesis is enhanced by COX-2 metabolism in the endothelium through the formation of 8,9,11-EHET. This alternative pathway for the metabolism of 8,9-EET may be particularly important in regulating angiogenesis under circumstances in which COX-2 is induced, such as in cancer tumor growth and inflammation.

arachidonic acid
endothelial cells
cyclooxygenase 2
mass spectrometry
cancer
metabolism
soluble epoxide hydrolase
angiogenesis

Cited by (0)

This work was supported by National Institutes of Health Grants RO1 ES0027010, P42 ES004699, R35 ES030443 (B.D.H.), T32 CA108459 (A.A.R.), and R01 HL082689 (A.G.P.); the 2016 American Association for Cancer Research Judah Folkman Fellowship for Angiogenesis Research (A.A.R.); and Natural Sciences and Engineering Research Council of Canada Grant RGPIN-2018-05330. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

The online version of this article (available at http://www.jlr.org) contains a supplement.

    Abbreviations:

    ARA

    arachidonic acid

    COX

    cyclooxygenase

    CYP

    cytochrome P450

    DHET

    dihydroxyeicosatrienoic acid

    EET

    epoxyeicosatrienoic acid

    EHET

    epoxy hydroxyeicosatrienoic acid

    HAEC

    human aortic endothelial cell

    PDBu

    phorbol 12,13-dibutyrate

    sEH

    soluble epoxide hydrolase

    t-AUCB

    trans-4-(4-(3-adamantan-1-yl-ureido)-cyclohexloxyl)-benzoic acid

    THET

    trihydroxyeicosatrienoic acid

    t-TUCB

    trans-4-[4-(3-trifluoromethoxyphenyl-l-ureido)-cyclohexyloxy]benzoic acid

    VEGF

    vascular endothelial growth factor

    VEGFR

    VEGF receptor